ID
42317
Description
Study ID: 108708 Clinical Study ID: 108708 Study Title: A phase IIb, controlled, randomized, multicentre, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 compared to a second dose of FluarixTM (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years previously vaccinated in FLU-LD-002 clinical trial Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00385840 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Influenza Vaccine GSK1247446A Trade Name: FluarixTM Study Indication: Influenza
Keywords
Versions (1)
- 5/29/21 5/29/21 -
Copyright Holder
GlaxoSmithKline
Uploaded on
May 29, 2021
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 NCT00385840
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
Similar models
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
C0019994 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0019994 (UMLS CUI [1,2])
C1522541 (UMLS CUI-2)
C0600091 (UMLS CUI [1,2])
No comments